B.Riley Financial Initiates ArriVent BioPharma(AVBP.US) With Buy Rating, Announces Target Price $37

Moomoo NewsMar 20 20:31 ET · Ratings

ArriVent Lead Drug Candidate Shows Promise In Lung Cancer Type, Analyst Sees Over 50% Upside

BenzingaMar 20 14:54 ET

This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

BenzingaMar 20 09:55 ET

B. Riley Securities Initiates Coverage On ArriVent BioPharma With Buy Rating, Announces Price Target of $37

BenzingaMar 20 05:17 ET · Ratings

ArriVent BioPharma Initiated at Buy by Guggenheim

Dow JonesMar 10 11:11 ET · Ratings

Guggenheim Initiates ArriVent BioPharma(AVBP.US) With Buy Rating, Announces Target Price $45

Moomoo NewsMar 10 07:31 ET · Ratings